Market Tracker

12/19 6:05pm ET

SPDR® S&P Pharmaceuticals ETF (XPH)

Data as of Dec 19
 -4.22 / -3.68%
Today’s Change
Today|||52-Week Range
XPH Combined Dividend: XPH began trading ex-dividend on 12/19/14. A combined dividend of 5.486776000000000 will be paid to shareholders of record as of 12/23/14.

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

No recent news for SPDR® S&P Pharmaceuticals ETF.


1 month+3.16% 3 years+33.86%
3 months+6.01% 5 years+27.01%
1 year+34.59% Since inception+18.04%
Data through 12/19/2014

Quote Details

Previous close$114.80
Open day’s range107.52 – 111.05
Net asset value (NAV)114.74 (12/18/2014)
Daily volume73,942
Average volume (3 months)67,801
Data as of 3:59pm ET, 12/19/2014

Peer Comparisonvs. Health ETFs

Performance 5-yr return+27.01%+21.83%
Expense Gross exp ratio0.35%0.44%
Risk 5 year sharpe ratio1.721.50
Net assets$1.1B$1.6B
Average market cap$8.9B$34.2B
Average P/E29.625.9
Dividend / Share--0.21%


VHT Vanguard Health Care Index Fund ETF Shar...
XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AUXL Auxilium Pharmaceuticals Inc4.60%
AVNR AVANIR Pharmaceuticals Class A4.48%
IPXL Impax Laboratories Inc3.96%
AGN Allergan Inc3.78%
MYL Mylan Inc3.73%
LCI Lannett Co Inc3.72%
ZTS Zoetis Inc3.72%
ABBV AbbVie Inc3.58%
BMY Bristol-Myers Squibb Company3.52%
ACT Actavis PLC3.46%